Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies

Area of Science:

• Mycology
• Immunology
• Infectious Diseases

Background:

• Candidiasis presents a high mortality rate and challenges due to antimicrobial resistance.
• Fungal beta-glucans are identified as key targets for novel antifungal therapies.
• Existing treatments face limitations, necessitating innovative approaches.

Purpose of the Study:

• To explore the potential of anti-beta-glucan antibodies in combating candidiasis.
• To investigate the role of beta-glucan cell wall killer toxin receptors in eliciting protective immunity.
• To assess the efficacy of anti-idiotypic antibodies and peptide mimotopes against pathogenic microorganisms.

Main Methods:

• Detection of anti-beta-glucan antibodies in sera.
• Elicitation of fungicidal protective activity using glucan-based vaccines.
• Utilizing killer toxin-neutralizing monoclonal antibodies as immunogens.
• Evaluating in vitro and in vivo microbicidal activity of antibodies and mimotopes.

Main Results:

• Anti-beta-glucan antibodies are present in animal and human sera.
• Glucan-based vaccines and killer toxin receptors can induce protective anticandidal antibodies.
• Anti-idiotypic anti-beta-glucan-like antibodies mediate anticandidal protection.
• Antibodies and mimotopes demonstrate microbicidal activity against various pathogens.

Conclusions:

• Anti-beta-glucan antibodies represent a viable strategy for candidiasis treatment and prevention.
• Targeting fungal beta-glucans offers a transphyletic approach to anti-infectious control.
• Immunoprevention and immunotherapy using anti-beta-glucan strategies hold significant therapeutic potential.